Ascendis Pharma

Business

Stifel Boosts Nurix Therapeutics Price Target to $35, Citing 2026 as Pivotal Year for Key Drug Candidate

Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.

Feb 2, 2026

Business

Jefferies Downgrades Amicus to 'Buy' Amid BioMarin Acquisition, Sees Limited Upside

Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.

Feb 2, 2026

Business

NETSTREIT's Rally Raises Valuation Questions: Is the REIT Still a Buy?

NETSTREIT Corp. (NYSE: NTST) has delivered impressive shareholder returns over the past year, significantly outpacing its longer-term performance. As the stock hovers near $19, investors and analysts are debating whether its current price fully reflects the fundamentals of this necessity-based retail REIT or if momentum has gotten ahead of value.

Feb 2, 2026

Business

Twist Bioscience Powers Ahead: Q1 2026 Revenue Jumps 17%, Fueled by AI-Driven Discovery Boom

Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.

Feb 2, 2026

Business

Curreen Capital's 'Crazy Cheap' Bet on Fortrea Pays Off as Fund Posts Strong 2025 Gains

Investment firm Curreen Capital, known for targeting undervalued 'ugly duckling' companies, highlighted contract research organization Fortrea Holdings as a prime example of its strategy in its latest investor letter. The firm reported a 30.97% return for 2025.

Feb 2, 2026

Business

Galenica's Five-Year Surge: A 90% Return for Patient Investors

Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.

Feb 2, 2026

Business

Sanofi's Pipeline Gains Momentum with Key Phase 3 Successes in Rare Disease and Immunology

Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.

Feb 2, 2026

Business

Revvity Beats Q4 Forecasts, Sets Bullish 2026 Targets on Diagnostics Strength

Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.

Feb 2, 2026

FDA Rejects Aquestive's Oral Anaphylaxis Treatment, Leaving Patients Awaiting Epinephrine Alternative

The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.

Feb 2, 2026

Business

Markets Edge Lower Ahead of Key Labor Data, Earnings Deluge

U.S. stock futures pointed to a lower open Monday as investors braced for a flood of corporate earnings and crucial labor market reports that could sway Federal Reserve policy expectations.

Feb 2, 2026

Business

Arctic Vision Bolsters Global Eye Care Ambitions with Strategic Acquisition of MDCO's Device Unit

Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.

Feb 2, 2026

Business

Wells Fargo Trims UnitedHealth Target by $30, Citing Medicare Advantage Headwinds

Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.

Feb 2, 2026

Business

Medicare's Obesity Drug Coverage Set to Fuel Lilly's Weight-Loss Pill Launch, CEO Says

Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.

Feb 2, 2026

Business

Insiders Bet Big on 908 Devices: A Vote of Confidence in the Future?

A wave of insider buying at 908 Devices Inc. has caught the market's attention, signaling potential optimism among those who know the company best. While not a guaranteed predictor, such coordinated activity often precedes significant corporate developments.

Feb 2, 2026

Business

InflaRx's Cash Runway Narrows: Can the Biotech Steer Through Financial Headwinds?

With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.

Feb 2, 2026

Business

Three Growth Stocks Poised to Outperform in a Volatile Market

Identifying companies with sustainable growth engines is a perennial challenge for investors. We analyze three firms—Vertiv, Ares Management, and Halozyme Therapeutics—that are expanding their competitive moats and delivering robust revenue growth, offering potential shelter in uncertain times.

Feb 2, 2026

Business

Navigating the Under-$10 Stock Market: One Opportunity Emerges as Two Others Face Challenges

While the sub-$10 stock universe offers potential for significant returns, it demands rigorous scrutiny. We analyze one company with a compelling growth thesis and two others where investors should proceed with caution.

Feb 2, 2026

Business

Factory Data Casts Shadow Over Markets: S&P 500 Futures Dip Amid Uneven Global Recovery Signals

U.S. stock futures retreated Monday as investors parsed a mixed bag of global manufacturing data, raising fresh questions about the durability of corporate earnings against a backdrop of cooling factory activity in key European economies.

Feb 2, 2026

Business

Healthcare Tech Stocks Navigate Turbulent Q3: Omnicell Surges While Peers Stumble

The third-quarter earnings season revealed a stark divergence in performance among leading healthcare technology providers. While Omnicell impressed with strong results and a soaring stock, peers like Evolent Health and Astrana Health faced significant market headwinds despite revenue beats.

Feb 2, 2026

Business

Three Global Stocks Trading at a Discount: Undervalued Picks for February 2026

Amid a market environment of stable rates and mixed sentiment, we highlight three companies—spanning biotech, gaming, and tech hardware—whose current share prices appear significantly below their estimated intrinsic value based on cash flow projections.

Feb 2, 2026